Start with its own history
At 30.05×, TARO is 58.1% above its 9-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

Current valuation, historical context, and peer comparisons.
Current P/E ratio
30.05×
58.1% abovethe 9-observation annual average
Price and EPS in quote currency. Calculation details
Investors are paying 30.05 for every 1 of reported earnings per share.
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2024 | 29.53× | -17.4% |
| Mar 31, 2023 | 35.76× | +28.1% |
| Mar 31, 2022 | 27.91× | N/M |
| Mar 31, 2021 | N/M | N/M |
| Mar 31, 2020 | 9.64× | -36.0% |
| Mar 31, 2019 | 15.06× | -19.8% |
| Mar 31, 2018 | 18.77× | +77.9% |
| Mar 31, 2017 | 10.55× | -7.0% |
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2016 | 11.35× | -9.0% |
| Mar 31, 2015 | 12.47× | -8.6% |
| Mar 31, 2014 | 13.64× | +38.6% |
| Mar 31, 2013 | 9.84× | -72.6% |
| Mar 31, 2012 | 35.95× | N/M |
| Dec 31, 2011 | N/M | N/M |
| Dec 31, 2010 | 9.11× | +198.6% |
| Dec 31, 2009 | 3.05× | -69.1% |
| Dec 31, 2008 | 9.87× | +26.9% |
| Dec 31, 2007 | 7.78× | N/M |
| Dec 31, 2006 | N/M | N/M |
| Dec 31, 2005 | 73.53× | -17.9% |
| Dec 31, 2004 | 89.55× | +194.3% |
| Dec 31, 2003 | 30.42× | +25.4% |
| Dec 31, 2002 | 24.26× | -32.6% |
| Dec 31, 2001 | 35.99× | +8.9% |
| Dec 31, 2000 | 33.05× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
TARO This stockTaro Pharmaceutical Industries Ltd. | 30.05× |
VIVOVivoPower PLC | N/M |
EMBCEmbecta Corp. | 4.04× |
ASTHAstrana Health, Inc. | 26.76× |
NXGNNextGen Healthcare, Inc. | N/M |
AMAMAmbrx Biopharma Inc. | N/M |
DCPHDeciphera Pharmaceuticals, Inc. | N/M |
PNTPOINT Biopharma Global Inc. | 12.02× |
FUSNFusion Pharmaceuticals Inc. | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
At 30.05×, TARO is 58.1% above its 9-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
The median of the 3 positive peer ratios above is 12.02×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore Wisesheets=WISE("TARO", "PE Ratio", "LQ")Share price 42.975 ÷ EPS 1.43 = 30.05×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Not supplied; this is not a real-time trading quote.
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
The essentials behind the numbers.